A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn's disease.
暂无分享,去创建一个
T. Hibi | J. Azuma | T. Kishimoto | A. Andoh | K. Yoshizaki | N. Nishimoto | Hiroaki Ito | T. Shimoyama | M. Takazoe | Y. Fukuda | K. Kusugami | T. Yamamura | T. Matsumoto
[1] Irving Kushner,et al. C-reactive Protein* , 2004, Journal of Biological Chemistry.
[2] T. Kishimoto,et al. Toxicity, pharmacokinetics, and dose-finding study of repetitive treatment with the humanized anti-interleukin 6 receptor antibody MRA in rheumatoid arthritis. Phase I/II clinical study. , 2003, The Journal of rheumatology.
[3] R. Price,et al. Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis: a randomized, double-blind, placebo-controlled, dose-escalation trial. , 2002, Arthritis and rheumatism.
[4] S. Hanauer. Maintenance infliximab for Crohn's disease , 2002, The Lancet.
[5] S. Hanauer,et al. For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .
[6] F. Shanahan. Crohn's disease , 2002, The Lancet.
[7] Simon A. Jones,et al. The soluble interleukin 6 receptor: mechanisms of production and implications in disease , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[8] R N Maini,et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. , 2000, The New England journal of medicine.
[9] T. Kishimoto,et al. IL-6 Is Required for the Development of Th1 Cell-Mediated Murine Colitis1 , 2000, The Journal of Immunology.
[10] M. Neurath,et al. Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: Evidence in Crohn disease and experimental colitis in vivo , 2000, Nature Medicine.
[11] Katsuki Ito,et al. Interleukin‐6 and soluble interleukin‐6 receptor in the colonic mucosa of inflammatory bowel disease , 1999, Journal of gastroenterology and hepatology.
[12] G. D'Haens,et al. Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: A European multicenter trial. , 1999, Gastroenterology.
[13] D. Furst,et al. Etanercept Therapy in Rheumatoid Arthritis , 1999, Annals of Internal Medicine.
[14] Simon A. Jones,et al. Brief Definitive Report C-reactive Protein: A Physiological Activator of Interleukin 6 Receptor Shedding , 1999 .
[15] Z Domljan,et al. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. , 1998, Arthritis and rheumatism.
[16] S. Targan,et al. A Short-Term Study of Chimeric Monoclonal Antibody cA2 to Tumor Necrosis Factor α for Crohn's Disease , 1997 .
[17] J. Grötzinger,et al. The Soluble Interleukin‐6 Receptor a , 1995, Annals of the New York Academy of Sciences.
[18] K. Tanikawa,et al. Soluble interleukin-6 receptors in inflammatory bowel disease: relation to circulating interleukin-6. , 1995, Gut.
[19] J. Rochon,et al. Quality of life: a valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease. Canadian Crohn's Relapse Prevention Trial Study Group. , 1994, Gastroenterology.
[20] J. Saldanha,et al. Reshaping a human antibody to inhibit the interleukin 6-dependent tumor cell growth. , 1993, Cancer research.
[21] J Y Mary,et al. Development and validation of an endoscopic index of the severity for Crohn's disease: a prospective multicentre study. Groupe d'Etudes Thérapeutiques des Affections Inflammatoires du Tube Digestif (GETAID). , 1989, Gut.
[22] T. Kishimoto,et al. The biology of interleukin-6. , 1989, Blood.
[23] C. Jacob,et al. Tumour necrosis factor-α in murine autoimmune 'lupus' nephritis , 1988, Nature.
[24] F Kern,et al. Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. , 1976, Gastroenterology.